Halozyme Announces SWOG Will Resume Clinical Trial of PEGPH20 In Combo with Modified FOLFIRINOX for Advanced Pancreatic Cancer

By: via Benzinga
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.